Melbourne, Australia: 19 December 2011, Starpharma (ASX: SPL; OTCQX SPHRY) today announced the advancement of its drug delivery collaboration with US pharmaceutical corporation Eli Lilly and Company.

 Starpharma has a number of projects underway with Lilly to improve the delivery of small molecule and protein-based pharmaceuticals using Starpharma’s dendrimer technology.

Based on results in the companies’ dendrimer-drug conjugate program, the parties have agreed to an expanded development program, incorporating further in vivo studies followed by clinical testing, as well as potential commercial terms should a product ultimately be brought to market.

The nature of the product and the associated commercial terms have not been disclosed due to confidentiality restrictions.

 “We are pleased to be able to report progress in our collaborations with Lilly,” said Dr Jackie Fairley, CEO Starpharma.  “We value the opportunity to advance our relationship with Lilly with these new arrangements.”

Download ASX Announcement: Starpharma's drug delivery program with Lilly advances ( pdf file, 101kb)